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Abstract
Background: A set of consistent, standardized definitions of intervals and populations on which to report across
provinces is needed to inform the Provincial/Territorial Deputy Ministries of Health on progress of the Ten-Year
Plan to Strengthen Health Care. The objectives of this project were to: 1) identify a set of criteria and variables
needed to create comparable measures of important time-to-cancer-care intervals that could be applied across
provinces and 2) use the measures to compare time-to-care across participating provinces for lung and colorectal
cancer patients diagnosed in 2004.
Methods: A broad-based group of stakeholders from each of the three participating cancer agencies was
assembled to identify criteria for time-to-care intervals to standardize, evaluate possible intervals and their
corresponding start and end time points, and finalize the selection of intervals to pursue. Inclusion/exclusion
criteria were identified for the patient population and the selected time points to reduce potential selection bias.
The provincial 2004 colorectal and lung cancer data were used to illustrate across-province comparisons for the
selected time-to-care intervals.
Results: Criteria identified as critical for time-to-care intervals and corresponding start and end points were: 1)
relevant to patients, 2) relevant to clinical care, 3) unequivocally defined, and 4) currently captured consistently
across cancer agencies. Time from diagnosis to first radiation or chemotherapy treatment and the smaller
components, time from diagnosis to first consult with an oncologist and time from first consult to first radiation
or chemotherapy treatment, were the only intervals that met all four criteria. Timeliness of care for the intervals
evaluated was similar between the provinces for lung cancer patients but significant differences were found for
colorectal cancer patients.
Conclusion: We identified criteria important for selecting time-to-care intervals and appropriate inclusion
criteria that were robust across the agencies that did not result in an overly selective sample of patients to be
compared. Comparisons of data across three provinces of the selected time-to-care intervals identified several
important differences related to treatment and access that require further attention. Expanding this collaboration
across Canada would facilitate improvement of and equitable access to quality cancer care at a national level.
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Background
The Ten-Year Plan to Strengthen Health Care, established
in September 2004 [1] by the Provincial/Territorial Dep-
uty Ministries of Health, united the Premiers of all Cana-
dian provinces through a national plan for healthcare in
the next decade. Improving access to and timeliness of
care were identified as high priority areas for improving
the Canadian health care system. As part of an exchange
for federal funding to the provincial health care system,
every province is expected to report "wait times" in five
priority areas, including cancer.
Each province has tackled this responsibility differently,
resulting in a set of inconsistently-defined intervals,
patient subsets, and metrics used to report "wait times"
that vary across provinces. In the case of cancer care, for
example, Alberta is monitoring time from referral to first
visit with an oncologist and time from the first visit to
treatment (for chemotherapy and radiation therapy sepa-
rately) [2], while Manitoba is monitoring time from
"ready to treat" to radiation therapy [3]. The health agen-
cies of most provinces post "wait time" data online [2-7]
in an attempt to be transparent and accountable to the
public. Without a standardized reporting system, how-
ever, that unifies the definitions of care-step intervals to
measure, patient populations to include, and metrics to
report, it is not possible to properly evaluate progress
across provinces for meeting the goals set forth in the Ten-
Year Plan. Specifically, a set of consistent, standardized
definitions of intervals and populations on which to
report across provinces would allow provincial health-
care agencies to discuss "wait times" in a unified manner,
make across-province comparisons to identify policy-rele-
vant strengths and deficiencies of each province in its care
system, and learn from each other towards the achieve-
ment of the national Ten-Year Plan.
A large body of literature exists on issues associated with
cancer care "wait times" nationally and internationally
[8], however, the variability of methodologies used make
comparison of results and use of information for deci-
sion-making difficult. In Canada, for example, there have
been nine "wait-time" studies that measured time to care
for colorectal and/or lung cancer patients [9-16]. All of
them focused on measuring aspects of time to radiation
therapy or time to surgery. Varying definitions of time
points, study designs, patient populations and reporting
metrics, however, make comparison of results impractical.
Analyzing data on timeliness of care in a comparative
fashion is a crucial research task for informing policy mak-
ers, health care providers, and other decision-makers
towards improving the quality of patient care.
To address these concerns, researchers in the cancer agen-
cies in three Canadian provinces (Alberta (AB), Saskatch-
ewan (SK), and Manitoba (MB)) formed a collaborative
team to develop and apply a unified methodology that is
practical and useful in comparing and learning from each
other, on time to cancer care in the three provinces. The
cancer agencies in these provinces are responsible for non-
surgical treatment of cancer in their jurisdictions. This
manuscript describes the methodology developed from
the collaboration and the overall analysis results as
applied to invasive lung and colorectal cancer cases diag-
nosed in 2004 as the source population.
Methods
To initiate the project, we identified and assembled a
group of stakeholders from each of the three cancer agen-
cies to participate in a workshop to identify steps that our
cancer agencies could take towards standardizing defini-
tions and measures of relevant cancer care intervals. At the
beginning of the workshop, presentations were made to
inform one another on current, planned, and future activ-
ities for measuring and reporting "wait times" at each of
the cancer agencies for both internal and external pur-
poses. Criteria to define "relevance" were then discussed
and identified. Various intervals and corresponding start
and end time points were suggested and evaluated with
respect to the criteria. Final intervals to pursue were then
selected that met the criteria and for which analysis and
evaluation could be completed within the one-year time
frame of the project were selected. The general consensus-
forming process was as follows. Ideas were generated via
brainstorming followed by open discussion, including
identification of pros and cons. Ideas were then synthe-
sized, discussed further, as needed, and then final priori-
ties and directions were voted on.
The expertise amongst stakeholders in the workshop was
broadly based and included senior management, epide-
miologists, surgeons, oncologists, nurses, a biostatisti-
cian, data analysts, quality assurance experts, system
developers, and programmers. Final decisions were made
by group consensus via informal voting after extensive
discussion in workshops. In addition to workshops
attended by the entire collaboration, a core group held
additional meetings to clarify the data elements available,
processes for data extraction, data completeness and qual-
ity, and ensure comparability of data across the three can-
cer agencies.
Consideration of time-to-care measurements as indicators
for timely access to care served as the underpinning for
discussions and decisions around the criteria for time
points and intervals. The following characteristics were
identified as requirements for standardizing such indica-
tors for cancer: 1) relevant to patients (as opposed to rele-
vant for internal organizational management), 2)
clinically relevant, 3) time points are unequivocally defin-BMC Cancer 2007, 7:186 http://www.biomedcentral.com/1471-2407/7/186
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able, and 4) practical in a sense that data for relevant time
points are routinely collected at the provincial cancer
agencies in a consistent and high quality manner.
Based on the four criteria, we evaluated potential start and
end time points for relevant time intervals. The time
points and intervals considered included those that were
being used in one of the three provinces and/or had been
proposed in the literature. This process led us to the final
time points and corresponding intervals to be used in the
project.
In addition to the definition and selection of time inter-
vals, we also identified inclusion criteria for the patient
population. We selected lung and colorectal cancers diag-
nosed in 2004 as exemplary tumor sites to be analyzed for
the purpose of evaluating and comparing measures for the
selected intervals. The reasons for this choice were: disease
incidence is high for both, they affect men and women,
and treatment includes the main cancer treatment modal-
ities (surgery, radiation, and chemotherapy) [17]. The two
cancers also contrast nicely in that prognosis is generally
poor for lung cancer but good for colorectal cancer [18].
All invasive colorectal (ICD-0 codes [19] C18, C19, C20,
C21, C260) and lung (ICD-0 codes [19] C33, C34) can-
cers diagnosed in 2004 in AB, SK, or MB that were of a
"typical histology" (see Table 1 for list of excluded histol-
ogies) [17] and for which the patient had an "opportunity
to receive treatment" were included in analyses; that is,
the date of diagnosis was not concurrent with the date of
death. In addition, dates of patient visits must be attribut-
able specifically to the cancer diagnosis of interest. Cur-
rently, electronic scheduling systems in all three cancer
agencies do not link a patient's diagnosis with their visits.
We, therefore, excluded patients with another invasive
[20] cancer diagnosis 183 days (6 months) prior to or
after the diagnosis of interest.
In addition to identifying inclusion criteria for patients, it
was also necessary to identify inclusion criteria for dates of
the endpoints of the intervals (e.g., diagnosis to treat-
ment). Initially data were evaluated that included dates
within 18 months of diagnosis. We found that 95% of the
patients received their first treatment in a cancer facility
within 6 months. The remaining patients either had
watchful waiting as their initial treatment plan or refused
the recommended first treatment. Upon investigation of
the data, we found that a very small proportion of patients
were meeting with an oncologist or receiving treatment
prior to diagnosis. This was a result of patients being
referred prior to having a definitive diagnosis or errors in
coding that have since been corrected. We, therefore,
included dates of visits in the range between 30 days prior
to diagnosis to 183 days (6 months) post-diagnosis.
The final dataset was reviewed by each province and qual-
ity assurance checks were run to ensure accuracy and com-
pleteness. Descriptive statistics and inverse Kaplan-Meier
[21] graphs were generated for each interval of interest;
the Log-Rank [22] test was used to test for differences
between curves. Estimates for the 50th and 90th percen-
Table 1: Sample selection criteria
Alberta Saskatchewan Manitoba
Colorectal Lung Colorectal Lung Colorectal Lung
N (%) N (%) N (%) N (%) N (%) N (%)
Diagnosed1,2 in 
2004
1688 (100) 1672 (100) 743 (100) 636 (100) 849 (100) 895 (100)
Exclusion 
criteria:
Non-invasive 74 (4) 2 (<1) 58 (8) 2 (<1) 36 (4) 15(2)
Uncommon3 
histology
10 (<1) 5 (<1) 3 (<1) 1 (<1) 1 (<1) 1 (<1)
Multiple4 
cancers
66 (4) 55 (3) 19 (3) 14 (3) 34 (4) 45 (5)
Dead at 
diagnosis
9 (<1) 17 (1) 21 (3) 52 (8) 17 (2) 34 (4)
Final 
population:
1529 (90) 1593 (95) 642 (86) 567 (89) 761 (90) 800 (89)
1- Diagnosis date defined by Canadian Cancer Registry coding rules [22(p67)]
2- Sites defined as in Canadian Cancer Statistics [16(p85)]
3- Leukemias, lymphomas, mesothelioma and Kaposi's sarcoma as defined in Canadian Cancer Statistics 2005 [16(p85)]
4- One or more invasive cancers within 6 months of the index case. Does not include non-melanoma skin cancer or insitu breast or bladder 
cancers as defined in [19(pp297-299)]BMC Cancer 2007, 7:186 http://www.biomedcentral.com/1471-2407/7/186
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tiles and their corresponding 95% confidence intervals
were calculated non-parametrically. Chi-squared tests
[22] were used to test differences between proportions.
SAS® version 9.1 (Cary, NC, USA) was used to create the
datasets and analyze them; graphs were made using
Microsoft Excel®.
Results
Table 2 describes the three Canadian provinces and their
respective cancer agencies. The cancer agencies are organ-
izationally and functionally similar and serve respective
provincial populations that are comparable.
The time points in a cancer patient care-trajectory that
were considered and their relationship to the four criteria,
described in the Methods, are summarized in Table 3. Only
four time points met all the criteria: dates of diagnosis,
first consult with an oncologist, first radiation, and first
chemotherapy. Date of diagnosis is captured by each
province's cancer registry according to the Canadian Can-
cer Registry coding rules [23], which define it as the earlier
of the date of the test for which the first pathological evi-
dence of cancer is available or the date of the first test on
which the treatment plan is based. The latter date is used
if the patient receives cancer treatment prior to or in the
absence of pathological evidence. Dates of first consult
with an oncologist, radiation treatment, and chemother-
apy are captured in each province's electronic medical
record system as part of their scheduling procedures.
Treatment dates are captured by both the cancer registry
(retrospectively) and by the cancer electronic medical
records (in real time).
We considered three intervals with the four time points
that satisfied the criteria; they were, time from: 1) diagno-
sis to first treatment in a cancer facility (that is, radiation
or chemotherapy), 2) diagnosis to first consult with an
oncologist, and 3) first consult with an oncologist to first
treatment in a cancer facility. Interval (1), above, was
selected as the primary interval of interest for comparison
because, of the three intervals, it is the best summary
measure of the total time-to-care experience of patients
post-diagnosis. Times from diagnosis to first consult and
from first consult to first radiation/chemotherapy were
agreed to be important components of the primary inter-
val. The provincial 2004 colorectal and lung cancer data
are used to illustrate across-province comparisons.
Table 1 lists the total number of cases diagnosed in 2004
and the number excluded by each province for each exclu-
sion criterion. Depending on the cancer site and province,
between 86% and 95% of the original sample was
retained after the exclusion criteria were applied. Table 4
lists the distribution of demographic characteristics of the
cases included in the final population by province and
cancer site (lung/colorectal cancer). The age and gender
distribution is similar across provinces and cancer sites.
The proportion of urban cases in each province is compa-
rable to the proportion of urban residents in each prov-
ince.
Figure 1 shows the cumulative proportion of patients who
received radiation or chemotherapy by the time elapsed in
days from diagnosis. The time interval is much shorter for
lung cancer patients than colorectal cancer patients. The
time from diagnosis to first radiation/chemotherapy is
significantly different across the provinces for both color-
ectal (P = 0.002) and lung cancer patients (P = .0061).
The curves shown in Figures 2 and 3 present the time from
diagnosis to first consult with an oncologist and time
from first consult to first radiation/chemotherapy, respec-
tively. From Figure 2 it can be seen that the time from
diagnosis to first consult was much shorter for lung cancer
patients than for colorectal cancer patients. In Figure 3,
however, the difference between tumor sites is negligible
indicating a similarity in speed of processing and treating
patients once they are seen at a cancer facility by an oncol-
ogist. The time intervals from diagnosis to consult and
consult to radiation/chemotherapy for colorectal cancer
Table 2: Description of provinces and corresponding cancer agencies
Province and cancer agency facts Alberta Saskatchewan Manitoba
Province:
Land area: 661,185 sq. km 651,900 sq. km 649,950 sq. km
Population: 3.1 million 1.0 million 1.2 million
Annual cancer incidence1: 12,000 5,000 5,600
Cancer Agency: # of cancer facilities2 that provide:
Radiation and chemotherapy: 2 2 1
Chemotherapy only: 14 13 14
Surgery: 0 0 0
Diagnostic imaging: 1 0 0
1- Exlcuding non-melanoma skin cancer
2- Facilities that are within the organizational structure of the cancer agencyBMC Cancer 2007, 7:186 http://www.biomedcentral.com/1471-2407/7/186
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patients were both significantly different across provinces
(P < 0.001 for both intervals). Colorectal cancer patients
in AB experienced a shorter time from diagnosis to consult
with an oncologist but a longer interval from consult to
radiation/chemotherapy than in SK or MB. No differences
were found in either interval for lung cancer, (P = 0.29 and
P = 0.17, respectively).
Table 5 summarizes the information in Figures 1, 2, 3
using the 50th and 90th percentiles of time to event in
days and their corresponding 95% confidence intervals,
by province and tumor site. Confidence intervals tend to
be fairly wide for all intervals. Although statistical differ-
ences identified graphically and in Table 5, based on sig-
nificance testing and overlapping confidence intervals,
respectively, are fairly consistent with one another, con-
clusions are likely to be different depending on the meas-
ure chosen for comparisons.
Discussion
The main goals of this project were to: 1) identify a set of
criteria and variables needed to create comparable meas-
ures of important time-to-cancer-care intervals that could
be applied across provinces and 2) to use the measures to
compare time-to-care across participating provinces for
lung and colorectal cancer patients diagnosed in 2004.
Extensive communication and inclusion of a broad set of
expertise ensured that the various perspectives of different
types of stakeholders were included in the consensus-
reaching process. This approach was needed to identify
appropriate inclusion criteria that were robust across the
agencies and did not result in an overly selective, or possi-
bly biased, sample of patients to be compared. Applica-
tion of the method to both lung and colorectal cancer
patients provided examples for different types of cancer
with different standard treatment practices.
Table 4: Distribution (percent) of patient demographics of final population
Colorectal Lung
Alberta 
(N = 1518)
SK 
(N = 642)
Manitoba 
(N = 749)
Alberta 
(N = 1585)
SK 
(N = 567)
Manitoba 
(N = 784)
Age1
< = 6 9 4 7 4 34 65 1 4 6 4 6
7 0 – 7 9 3 1 3 43 13 3 3 6 3 4
> = 8 0 2 2 2 32 41 5 1 8 2 0
Gender
Female 44 46 47 47 46 48
Male 56 54 53 53 54 52
Region2
U r b a n 6 2 5 05 56 3 5 0 5 7
R u r a l 3 8 5 04 53 7 5 0 4 3
1 -Percents may not add to 100 due to rounding
2 -Urban defined as living in a health region with major cancer facility (i.e., health regions containing the cities of Edmonton, Calgary, Regina, 
Saskatoon, or Winnipeg) at time of diagnosis.
Table 3: Time points and criteria for selecting standardized time-to-care intervals
Time points Criteria
Date of first: Relevant to patients Relevant to clinical care Unequivocally defined Currently captured1
Symptom onset Yes Yes No No
Diagnosis Yes Yes Yes Yes
Referral to cancer facility Consensus not reached2 Consensus not reached2 No No
Consult with oncologist Yes Yes Yes Yes
Ready to treat No Consensus not reached2 No No
Surgery Yes Yes Yes No
Radiation Yes Yes Yes Yes
Chemotherapy Yes Yes Yes Yes
1 – If time point is currently captured routinely and consistently by the cancer agencies of AB, SK, and MB then 'Yes' otherwise 'No.'
2 – Consensus regarding the relevance of the time point was not reached by the participants in the workshop in the process described in the 
Methods.BMC Cancer 2007, 7:186 http://www.biomedcentral.com/1471-2407/7/186
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Differences observed between provinces in the intervals
depicted in Figures 2 and 3 for colorectal cancer patients
suggest each cancer agency could learn from another to
shorten the intermediary care intervals and subsequently
shorten the overall diagnosis to first radiation/chemother-
apy interval. Differences in time-to-care could be due to
differences across provinces in the distribution of patient/
disease charateristics, referral patterns, and/or treatment
patterns, in addition to care-delivery differences. Patient
characteristics were, however, comparable across the
provinces (see Table 4). The distribution of stage at diag-
nosis for colorectal cancer patients across the provinces
was also comparable (data not shown). Further investiga-
tions into referral patterns and treatment practices in the
three provinces are underway to understand and explain
the differences seen.
In Figures 1 and 2, the differences between lung and color-
ectal cancer patients are largely due to differences in treat-
ment practice. Roughly 85% of the colorectal cancer
patients had surgery prior to radiation or chemotherapy,
whereas only about 13% of the lung cancer patients did.
Surgery is more likely to be a colorectal cancer patient's
first treatment while radiation or chemotherapy is more
likely to be a lung cancer patient's first treatment. To a
large extent then, these graphs represent time to first and
second treatment for lung and colorectal cancer patients,
respectively. Comparable differences would be expected
to be seen between any tumor sites with similarly different
order in their treatment modalities.
Ideally, one would like to compare time from diagnosis to
first treatment and time from first treatment to second
treatment. This, however, is not currently possible at a
national level in Canada because a major treatment
modality, surgery, is performed outside of the cancer
agencies and many cancer agencies do not have routine
access to cancer surgery data. Until dates for treatments
received outside cancer agencies are routinely available,
Cumulative time from first consult visit with an oncologist to  first radiation or chemotherapy treatment by tumor site and  province Figure 3
Cumulative time from first consult visit with an oncologist to 
first radiation or chemotherapy treatment by tumor site and 
province.
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Cumulative time from diagnosis to first radiation or chemo- therapy treatment by tumor site and province Figure 1
Cumulative time from diagnosis to first radiation or chemo-
therapy treatment by tumor site and province.
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Cumulative time from diagnosis to first consult visit with an 
oncologist by tumor site and province.
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however, reporting time from diagnosis to first treatment
oferred at the cancer agency is practical; at the very least it
should be comparable for most Canadian cancer agencies.
Based on an unpublished survey conducted by the Can-
dian Association of Provincial Cancer Agencies (CAPCA)
in 2006 at least seven provinces in Canada have the dates
of diagnosis, consult with oncologist and first treatment
in a cancer facility; the other three provinces may not have
dates related to chemotherapy readily available (this
information was not specifically captured in the survey)
but have diagnosis date and dates related to radiation
(consultations and treatment).
The Health Council of Canada recommends the defini-
tion of a waiting interval be time from initial referral to
completion of the procedure [24]. "Initial referral," in the
context of cancer care, however, can have several mean-
ings since patients may have multiple "initial" referrals as
they are referred to surgeons and various types of oncolo-
gists. The clock of "waiting," however, begins at the time
of diagnosis for the patient, thus diagnosis is a more
appropriate start time. Furthermore, delays that occur
between diagnosis and any of these "initial" referrals may
be clinically relevant to quality of patient care. Regarding
reporting, the Health Council suggests reporting the dura-
tion in 90th or 95th percentiles and adds that a wait-time
reporting system should inform on the time for typical
cases relative to existing benchmarks, duration of interval
for outliers, and changes over time. Information on time-
to-care alone is not enough, however, to properly inform
policy on quality of care for cancer. Additional informa-
tion such as the proportion of patients receiving certain
care steps is also needed; short time-to-care intervals do
not equal high quality if a large percentage of patients
who should be receiving care are not.
An important limitation in the process used to identify cri-
teria and select relevant time intervals was that we had one
year of funding to perform the work; this prevented us
from considering time points that were not currently
being collected by our cancer agencies or pursuing exter-
nal data sources. This restriction also prevented us from
considering points of care that fall outside the care of the
cancer agencies such as pre-diagnosis and post-treatment
follow-up; equally important intervals of care for which
information related to timeliness of care is needed. Due to
the limited timeframe, our intent was to identify an initial
step towards standardizing defintions and measures
related to timeliness of care that would facilitate future
decision-making and identify directions that would even-
tually include the cancer care continuum. In this intial
step we did not include patients in our decision-making
process which is also a limitation. A limitation in inter-
preting the analytic results is that although differences
between tumor sites and provinces can be detected, addi-
tional data and information are needed to identify why
differences exist.
Conclusion
In summary, production of standardized "wait-time" data
across Canadian provinces will allow identification at the
national level of problems which facilitate solutions and
changes to current resource allocation and overall system
improvements. Interpretation of the data in the context of
practice guidelines, particularly as related to treatment
modality and order, is essential to avoid incorrect inter-
pretation of apparant relative delays. Production of stand-
ardized "wait-time" data requires close collaboration, at
least initially, between the provinces to ensure compara-
bility. This activity in and of itself may facilitate adoption
of more efficient processes or models of care as differences
and strengths between provinces are identified. Infrastruc-
ture must be developed to obtain dates of cancer surgery
to enable comparisons of diagnosis to first and second
treatment as well as facilitate evaluation of appropriate
care.
Although there are many similarities between AB, SK, and
MB with respect to the size of the provinces and organiza-
tion of the cancer agencies, this collaboration has enabled
Table 5: Median and 90th percentile estimates for time-to-care for each care interval by cancer site and province
# days from diagnosis to 1st 
radiation or chemotherapy
# days from diagnosis to consult # days from consult to 1st radiation 
or chemotherapy
Median (95% CI) 90% (95% CI) Median (95% CI) 90% (95% CI) Median (95% CI) 90% (95% CI)
Colorectal
Alberta 69 (67, 74) 115 (110, 124) 50 (48, 53) 95 (89, 104) 21 (20, 21) 62 (56, 70)
Saskatchewan 77 (73, 85) 139 (132, 150) 63 (59, 69) 120 (113, 122) 14 (13, 18) 41 (36, 48)
Manitoba 74 (70, 77) 132 (122, 144) 57 (54, 60) 118 (107, 127) 14 (12, 19) 64 (51, 77)
Lung
Alberta 31 (29, 34) 91 (84, 99) 25 (23, 26) 81 (72, 90) 8 (8, 9) 33 (30, 35)
Saskatchewan 41 (35, 45) 91 (80, 112) 30 (27, 33) 82 (71, 99) 10 (8, 14) 34 (30, 41)
Manitoba 36 (29, 41) 109 (95, 119) 25 (22, 28) 78 (70, 95) 8 (7, 12) 46 (41, 55)Publish with BioMed Central    and   every 
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us to identify several important differences related to
treatment and access that require further attention. We
expect that there are changes each organization could
make that would decrease these differences resulting in
improved access and quality of care for cancer patients.
Expanding this collaboration across Canada would facili-
tate improvement of and equitable access to quality can-
cer care at a national level and reaching the goal of the
Ten-Year Plan to Strengthen Health Care in Canada.
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